New surgery reduces the rate of spinal tuberculosis
Release date: 2006-11-01
A groundbreaking approach has significantly lowered the recurrence rate of spinal tuberculosis. The Department of Orthopaedics at the Affiliated Hospital of Ningxia Medical College challenged traditional methods by introducing short-course chemotherapy combined with partial vertebral resection, offering a more effective and less invasive treatment for this severe condition. As a result, the reoperation rate dropped dramatically from 28% to just 0.54%. This innovative research, which took eight years to complete, was awarded the first prize in the 2005 Ningxia Autonomous Region Science and Technology Progress Award and was showcased at the National Health Science and Technology Conference.
According to Wang Zili, head of the orthopedic department and lead researcher, spinal tuberculosis accounts for 40% to 75% of all bone and joint tuberculosis cases, primarily affecting children and young adults. Given that Ningxia is a high-risk area for tuberculosis—ranking second in prevalence nationwide—the need for improved treatment methods is critical.
Wang and his team pioneered a new strategy by moving away from conventional lesion removal surgery. Instead, they performed partial resection of the affected area, preserving the surrounding hardened tissue while targeting the infected regions. This was followed by three different chemotherapy regimens: ultra-short-course, short-course, and standard chemotherapy. All three approaches showed excellent results, with no patients experiencing relapses.
Among these, the combination of ultra-short-course chemotherapy and partial resection stood out. It reduced the treatment duration from 1.5 to 2 years down to just 4.5 months, without compromising the cure rate compared to the other groups. This not only eased the burden on both patients and the healthcare system but also improved patient compliance and reduced the risk of drug resistance due to irregular medication. This advancement has made treatment more accessible and efficient for those suffering from spinal tuberculosis.
The new method has since been widely adopted across medical institutions in Ningxia, Guangdong, and Shaanxi provinces. This breakthrough represents a major step forward in the fight against spinal tuberculosis, offering hope and better outcomes for patients across China.
Sildenafil is a selective inhibitor of cyclic guanosine monophosphate (CGMP) - specific phosphodiesterase 5 (PDE5) and an oral drug for the treatment of ED. The physiological mechanism of normal penile erection involves the release of nitric oxide (no) during sexual stimulation. Nitric oxide activates guanylate cyclase in the smooth muscle cells of the corpus cavernosum, which leads to the increase of cGMP level, resulting in the relaxation of the smooth muscle in the corpus cavernosum, the expansion of the cavernous sinus and the inflow of blood. Erectile dysfunction is mainly due to the dysfunction of smooth muscle relaxation of corpus cavernosum. Sildenafil has no direct relaxation effect on human sponges in vitro, but can enhance the effect of nitric oxide by inhibiting the decomposition of cGMP by PDE5 in sponges. Sildenafil can inhibit PDE5, increase cGMP level, relax smooth muscle of corpus cavernosum and let blood flow into corpus cavernosum. Studies have shown that erectile response increases with the increase of dose and plasma concentration, and the efficacy can last for 4 hours (but is weaker than that at 2 hours).
Sarms Capsules,Sildenafil Capsules,Healthcare Capsules,Herbal Capsules
Xi'an Tian Guangyuan Biotech Co., Ltd. , https://www.tgybiotech.com